Scarica l'app Stockscreener
341.66
5.66%
18.29
Pre-mercato:
344.51
2.85
+0.83%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KRYS Giù?
Forum
Previsione
Precedente Chiudi:
$323.37
Aprire:
$323.55
Volume 24 ore:
514.58K
Relative Volume:
1.81
Capitalizzazione di mercato:
$10.07B
Reddito:
$417.30M
Utile/perdita netta:
$225.03M
Rapporto P/E:
45.67
EPS:
7.4815
Flusso di cassa netto:
$237.38M
1 W Prestazione:
+9.36%
1M Prestazione:
+11.55%
6M Prestazione:
+44.89%
1 anno Prestazione:
+162.77%
Intervallo 1D:
$322.95
$347.67
Intervallo di 1 settimana:
$312.25
$347.67
Portata 52W:
$127.99
$347.67
Krystal Biotech Inc Stock (KRYS) Company Profile
Nome
Krystal Biotech Inc
Settore
Industria
Telefono
(412) 586-5830
Indirizzo
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
341.66 | 9.57B | 417.30M | 225.03M | 237.38M | 7.4815 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-27 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-05 | Iniziato | Jefferies | Buy |
| 2024-08-06 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Iniziato | Citigroup | Buy |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-18 | Iniziato | Stifel | Buy |
| 2023-02-28 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-18 | Iniziato | BofA Securities | Buy |
| 2021-07-20 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-18 | Iniziato | B. Riley FBR | Buy |
| 2020-06-04 | Iniziato | Evercore ISI | Outperform |
| 2019-09-24 | Iniziato | Goldman | Neutral |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-24 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-30 | Iniziato | Guggenheim | Buy |
| 2018-09-11 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Krystal Biotech Inc Borsa (KRYS) Ultime notizie
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism - Stocktwits
Krystal Biotech, Inc. (KRYS) Stock Analysis: Evaluating the 31.9% Revenue Growth and Its Implications for Investors - DirectorsTalk Interviews
Krystal Biotech, Inc. (KRYS) tops Q1 earnings and revenue estimates - MSN
Krystal Biotech stock soars 16% in three months: Here's why - MSN
Krystal Biotech stock hits all-time high at 319.6 USD By Investing.com - Investing.com Nigeria
Krystal Biotech stock hits all-time high at 319.6 USD - Investing.com
Cash per share of Krystal Biotech, Inc. – MUN:4KB - TradingView
This Insider Has Just Sold Shares In Krystal Biotech - simplywall.st
Is the options market predicting a spike in Krystal Biotech stock? - MSN
Krystal Biotech, Inc. (KRYS) Stock Analysis: Strong Buy Ratings and a Promising 7.24% Potential Upside - DirectorsTalk Interviews
Krystal Biotech Insider Sold Shares Worth $7,702,984, According to a Recent SEC Filing - marketscreener.com
Is Krystal Biotech, Inc. (KRYS) A Good Stock To Buy Now? - Insider Monkey
Krystal Biotech, Inc. Cash Flow – XETR:4KB - TradingView
Krystal Biotech, Inc. Balance Sheet – XETR:4KB - TradingView
ETFs Investing in Krystal Biotech, Inc. Stocks - TradingView
Krystal Biotech CEO Krishnan sells $7.7m in company stock By Investing.com - Investing.com South Africa
Krystal Biotech CEO Krishnan sells $7.7m in company stock - Investing.com UK
Krystal Biotech R&D president Suma Krishnan sells $7.7m in stock By Investing.com - Investing.com South Africa
Krystal Biotech(KRYS.US) 10% Shareholder Sells US$7.7 Million in Common Stock - Moomoo
Krystal Biotech R&D president Suma Krishnan sells $7.7m in stock - Investing.com Canada
25K-share sale by Krystal Biotech (NASDAQ: KRYS) R&D head - Stock Titan
Krystal Biotech (KRYS) CEO trades 25,000 shares under 10b5-1 plan - Stock Titan
Krystal Biotech Inc stock (US5012681064): shares steady after strong Q1 2026 earnings momentum - AD HOC NEWS
Is the Options Market Predicting a Spike in Krystal Biotech Stock? - Zacks Investment Research
The Technical Signals Behind (KRYS) That Institutions Follow - Stock Traders Daily
[144] Krystal Biotech, Inc. SEC Filing - Stock Titan
Krystal Biotech Stock Soars 16% in Three Months: Here's Why - The Globe and Mail
KRYS Technical Analysis | Trend, Signals & Chart Patterns | KRYSTAL BIOTECH INC (NASDAQ:KRYS) - ChartMill
Why is Krystal Biotech (KRYS) up 3% since last earnings report? - MSN
Why Is Krystal Biotech (KRYS) Up 3% Since Last Earnings Report? - Yahoo Finance
Analysts Have Conflicting Sentiments on These Healthcare Companies: Krystal Biotech (KRYS), AbbVie (ABBV) and Tempus AI, Inc. Class A (TEM) - The Globe and Mail
KRYS Reiterates by HC Wainwright & Co. -- Price Target Maintained at $310 - GuruFocus
Krystal Biotech, Inc. (KRYS) Stock Analysis: A Biotech Powerhouse with 31.90% Revenue Growth and Potential Upside - DirectorsTalk Interviews
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $364 - Moomoo
Krystal Biotech (BSP:K1YS34) Equity Investments - GuruFocus
KRYS Technical Analysis & Stock Price Forecast - Intellectia AI
Exploring High Growth Tech Stocks In The US Market May 2026 - simplywall.st
Insider Sell: John Thomas Sells Shares of Krystal Biotech Inc (K - GuruFocus
Insider Sell: John Thomas Sells Shares of Krystal Biotech Inc (KRYS) - GuruFocus
Krystal Biotech EVP, general counsel sells $193,903 in shares - Investing.com
Krystal Biotech EVP, general counsel sells $193,903 in shares By Investing.com - Investing.com Australia
Krystal Biotech Inc Azioni (KRYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Krystal Biotech Inc Azioni (KRYS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Krishnan Krish S | President and CEO |
Jun 04 '26 |
Sale |
308.12 |
25,000 |
7,702,984 |
1,450,253 |
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):